 3. Pancreatic neuroendocrine patients must have had progression after prior therapy. Patients with other foregut neuroendocrine tumors must have had progressive disease over the last 12 months, irrespective of prior therapy. Patients with both functional who may continue somatostatin analogues as required for control of related symptoms and non-functional tumors are eligible. In patients who have previously received therapy, the number of prior lines of therapy should not be more than 2 lines of systemic therapy not including somatostatin analogues. 